MIDAZOLAM
Cholangitis
National University of MalaysiaSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Cholangitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ceftriaxone Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 | BB |
L-Ofloxacin University of Southern California | Phase 4 | BB |
NORMAL HUMAN SERUM ALBUMIN EASL - CLIF Consortium | Phase 4 | BB |
htd1801 HighTide Biopharma Pty Ltd | Phase 2 | B |
Meperidine National University of Malaysia | Phase 2 | B |
View all 19 →
Same molecule, other indications
MIDAZOLAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →